Barclays PLC Acumen Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 61,997 shares of ABOS stock, worth $109,734. This represents 0.0% of its overall portfolio holdings.

Number of Shares

61,997

Previous 61,997 -0.0%

Holding current value

$109,734

Previous $154,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$2.22 - $3.54 $90,023 - $143,550	40,551 Added 189.08%	61,997 $154,000
Q2 2024 Aug 14, 2024	SELL	$2.14 - $4.01 $55,348 - $103,714	-25,864 Reduced 54.67%	21,446 $52,000
Q1 2024 May 15, 2024	SELL	$2.97 - $4.64 $109 - $171	-37 Reduced 0.08%	47,310 $191,000
Q4 2023 Feb 15, 2024	BUY	$1.86 - $4.48 $46,354 - $111,650	24,922 Added 111.13%	47,347 $182,000
Q3 2023 Nov 07, 2023	SELL	$4.15 - $9.72 $12,321 - $28,858	-2,969 Reduced 11.69%	22,425 $93,000
Q2 2023 Aug 03, 2023	SELL	$3.59 - $6.59 $2,003 - $3,677	-558 Reduced 2.15%	25,394 $122,000
Q1 2023 May 04, 2023	SELL	$3.75 - $6.65 $31,908 - $56,584	-8,509 Reduced 24.69%	25,952 $105,000
Q4 2022 Feb 13, 2023	BUY	$4.81 - $10.17 $1,442 - $3,051	300 Added 0.88%	34,461 $185,000
Q3 2022 Nov 03, 2022	BUY	$4.44 - $10.48 $121,820 - $287,539	27,437 Added 408.05%	34,161 $342,000
Q2 2022 Aug 12, 2022	SELL	$3.08 - $4.88 $15,686 - $24,853	-5,093 Reduced 43.1%	6,724 $32,000
Q1 2022 May 16, 2022	BUY	$3.91 - $6.73 $46,204 - $79,528	11,817 New	11,817 $46,000

Others Institutions Holding ABOS

# of Institutions

Shares Held

41.8M

Call Options Held

57.7K

Put Options Held

749K

View Full List

About Acumen Pharmaceuticals, Inc.

Ticker ABOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,503,100
Market Cap $71.7M
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...

More about ABOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account